Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Mycobacterium Avium-Intracellulare Infection; HIV Infections
Intervention: Rifapentine (Drug); Ethambutol hydrochloride (Drug); Clarithromycin (Drug); Azithromycin (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Anderson Clinical Research
Summary
To determine the antimicrobial activity and tolerability of rifapentine alone and in
combination therapy in patients with AIDS and disseminated Mycobacterium avium complex (MAC)
bacteremia. To determine the pharmacokinetics of rifapentine and its metabolite,
25-desacetyl, alone and in combination therapy. To determine the pharmacokinetics of
azithromycin and clarithromycin (and its 14-OH metabolite) in combination therapy.
Clinical Details
Official title: Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.
Study design: Treatment, Safety Study
Detailed description:
This open-label, sequential study is conducted in two parts: a monotherapy phase and a
combination treatment phase.
In the monotherapy phase sequential 3-patient cohorts receive 1 of 3 doses of rifapentine
monotherapy.
In the combination treatment phase, 12 patients each are randomized to one of three arms:
Arm I: Rifapentine (assigned dose level based on monotherapy phase) plus azithromycin.
Arm II: Rifapentine (assigned dose level) plus clarithromycin. Arm III: Rifapentine (assigned
dose level) plus ethambutol.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
Patients must have:
- Documented positive HIV serology status.
- Documented AIDS.
- Positive blood culture for MAC from the study-designated microbiology laboratory.
NOTE:
- Patients with presumed MAC bacteremia, as evidenced by positive blood, bone marrow, or
liver biopsy culture analyzed locally, may be enrolled pending confirmation.
- Minimum of two MAC-associated symptoms, defined as >= grade 1 fever; > grade 1 night
sweats, fatigue, diarrhea, abdominal pain, or anorexia; or weight loss > 5% reported
within 4 weeks prior to study entry.
- Life expectancy of at least 3 months.
Prior Medication:
Allowed:
MAC prophylaxis with medications other than study drugs (5-day washout period required).
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Pulmonary tuberculosis.
- Infections requiring the use of disallowed medications.
- Serious diseases that introduce undue risks for adverse reactions to study
medication.
Concurrent Medication:
Excluded:
- Terfenadine.
- Treatment for pulmonary TB.
- Study drugs from an outside source.
- Medications with anti-MAC activity (i. e., amikacin, ciprofloxacin, clofazimine,
rifampin, and rifabutin).
Patients with the following prior conditions are excluded:
- History of hypersensitivity to rifabutin, rifampin, clarithromycin, erythromycin,
azithromycin, or ethambutol.
- Previous episode of uveitis.
Prior Medication:
Excluded:
- Prophylactic treatment for MAC with rifabutin or any of the study medications.
- Azithromycin within the 3 weeks prior to randomization.
- Any investigational drug during the 4 weeks prior to randomization.
Locations and Contacts
Hampton Roads Med Specialists, Hampton, Virginia 23666, United States
Additional Information
Last updated: June 23, 2005
|
